Inflammation Chem. Head at Roche to give featured talk at Protein Kinases meeting May 27-28, Boston

Printer-friendly versionPDF version

David M. Goldstein, Senior Director and Head of Inflammation Chemistry at Hoffmann-La Roche will give a featured presentation on “Using In-Vitro Assays, including Kinase Selectivity Profiles, to Predict Toxicity In-Vivo” at the 5th Annual Protein Kinases in Drug Discovery conference to be held this year in Boston, MA on May 27-28, 2010 by GTCbio.

MONROVIA, CA – David M. Goldstein, Senior Director and Head of Inflammation Chemistry at Hoffmann-La Roche to speak at GTCbio’s 5th Protein Kinases in Drug Discovery conference May 27-28, 2010 in Boston, MA.

David M. Goldstein will give a featured presentation on “Using In-Vitro Assays, including Kinase Selectivity Profiles, to Predict Toxicity In-Vivo”. Internal experience with kinase inhibitors has identified multiple safety liabilities which often manifest themselves only after prolonged treatment in vivo. At Roche, an initiative between chemistry, research informatics and safety was established to create predictive tools to improve their current attrition rate.

Benefits of Dr. Goldstein’s presentation include:
• Robust toxicity of kinase inhibitors can be leveraged to validate new in-vitro assays
• Demonstrate how kinase inhibition profiles can be utilized to predict toxicities
• Early safety information can help project teams make decisions faster and more efficiently

David M. Goldstein received his Ph.D. in organic chemistry from the Department of Chemistry at the University of Virginia in 1992. From 1992-1994, he completed post-doctoral studies in organic chemistry at the University of Pittsburgh under the direction of Prof. Peter Wipf. In 1994, he joined Syntex in Palo Alto, California and continued on with Roche in 1995. Currently, he is a Senior Director and the Head of Inflammation Chemistry at Roche in Nutley, New Jersey. David’s research is focused on the discovery of small molecule inhibitors in the areas of inflammatory, respiratory and autoimmune diseases. David has an active interest in the development of new in-vitro tools to enable early safety profiling of drug candidates.